Skip to content
OpenCapital
Get started

Viridian Therapeutics, Inc. VRDN Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
——
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
——

Other financials

Income statement

See full
Revenue$141.0K+95.8%
Operating income-$116.2M-23.8%
Net income-$104.9M-20.7%
EPS (diluted)-$1.15-5.5%

Balance sheet

See full
Cash & equivalents$176.3M+51.7%
Total debt$36.8M+59.4%
Total equity$636.0M+5.2%
Total assets$789.0M+19.4%

Cash flow

See full
Operating cash flow-$119.7M-29.1%
CapEx$23.0K-73.3%
Free cash flow-$119.7M-29.0%

Valuation

See full
Market cap$1.91B+82.0%
Enterprise value$1.77B+85.0%
P/S26.9×-3,445×

Profitability

See full
Gross margin36.3%—
Operating margin-543.9%-271pp
Net margin-508.5%-254pp
FCF margin-428.4%-214pp

Returns & leverage

See full
Return on equity-58.1%+7.9pp
Debt / equity0.1×0.0×
Current ratio15.1×-4.3×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viridian Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viridian Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities?
Viridian Therapeutics, Inc. (VRDN) reported proceeds from sale and maturity of available for sale securities of $168.6M in Q1 2026.
How has Viridian Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities changed year-over-year?
Viridian Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities decreased by 1.6% year-over-year, from $171.39M to $168.6M.
What is the long-term trend for Viridian Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities?
Over 3 years (2022 to 2025), Viridian Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities has grown at a 70.7% compound annual growth rate (CAGR), from $108.94M to $542.21M.